All news

T. Rowe Price updates its reported Vaxcyte (PCVX) stake, with sole voting power over 13.7M shares.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

T. Rowe Price Investment Management, Inc. has updated its beneficial ownership in Vaxcyte, Inc. (PCVX), reporting a 9.6% stake, which equates to 14,312,368 common shares. The investment manager holds sole voting power over 13,699,251 shares and sole dispositive power over all 14,312,368 shares. This disclosure was made in an amended SCHEDULE 13G/A filing with the SEC.

Read original source

TROW company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.